Tags

Type your tag names separated by a space and hit enter

Endocannabinoid chemical biology: a tool for the development of novel therapies.
Curr Opin Chem Biol 2009; 13(3):309-20CO

Abstract

The identification of the major psychoactive constituent of Cannabis and marijuana, Delta(9)-tetrahydrocannabinol, opened the way first to the cloning of the G-protein-coupled cannabinoid CB(1) and CB(2) receptors, and then to the isolation and characterisation of their endogenous agonists, the endocannabinoids. Considerable progress has been made in the characterisation of pathways and enzymes for the biosynthesis and degradation of anandamide and 2-arachidonoylglycerol, the two best-known endocannabinoids, as well as of endocannabinoid-related molecules, such as the N-acylethanolamines, which, as in the case of N-palmitoylethanolamine and N-oleoylethanolamine, may interact with other receptor types. However, it is still not fully understood how other plant cannabinoids, of which cannabidiol is the most studied representative, exert their pharmacological effects. Together with these issues, this first review article on the endocannabinoids describes the synthetic pharmacological tools that have been designed so far to interact with the proteins of the 'endocannabinoid system' and that can potentially be used as templates for the development of new therapies.

Authors+Show Affiliations

Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy. spetrosino@icmib.na.cnr.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19457702

Citation

Petrosino, Stefania, et al. "Endocannabinoid Chemical Biology: a Tool for the Development of Novel Therapies." Current Opinion in Chemical Biology, vol. 13, no. 3, 2009, pp. 309-20.
Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr Opin Chem Biol. 2009;13(3):309-20.
Petrosino, S., Ligresti, A., & Di Marzo, V. (2009). Endocannabinoid chemical biology: a tool for the development of novel therapies. Current Opinion in Chemical Biology, 13(3), pp. 309-20. doi:10.1016/j.cbpa.2009.04.616.
Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid Chemical Biology: a Tool for the Development of Novel Therapies. Curr Opin Chem Biol. 2009;13(3):309-20. PubMed PMID: 19457702.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endocannabinoid chemical biology: a tool for the development of novel therapies. AU - Petrosino,Stefania, AU - Ligresti,Alessia, AU - Di Marzo,Vincenzo, Y1 - 2009/05/18/ PY - 2009/03/17/received PY - 2009/04/17/accepted PY - 2009/5/22/entrez PY - 2009/5/22/pubmed PY - 2009/10/1/medline SP - 309 EP - 20 JF - Current opinion in chemical biology JO - Curr Opin Chem Biol VL - 13 IS - 3 N2 - The identification of the major psychoactive constituent of Cannabis and marijuana, Delta(9)-tetrahydrocannabinol, opened the way first to the cloning of the G-protein-coupled cannabinoid CB(1) and CB(2) receptors, and then to the isolation and characterisation of their endogenous agonists, the endocannabinoids. Considerable progress has been made in the characterisation of pathways and enzymes for the biosynthesis and degradation of anandamide and 2-arachidonoylglycerol, the two best-known endocannabinoids, as well as of endocannabinoid-related molecules, such as the N-acylethanolamines, which, as in the case of N-palmitoylethanolamine and N-oleoylethanolamine, may interact with other receptor types. However, it is still not fully understood how other plant cannabinoids, of which cannabidiol is the most studied representative, exert their pharmacological effects. Together with these issues, this first review article on the endocannabinoids describes the synthetic pharmacological tools that have been designed so far to interact with the proteins of the 'endocannabinoid system' and that can potentially be used as templates for the development of new therapies. SN - 1879-0402 UR - https://www.unboundmedicine.com/medline/citation/19457702/abstract/ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1367-5931(09)00061-1 DB - PRIME DP - Unbound Medicine ER -